Risk of heart disease following breast cancer: results from a population-based cohort study

Haomin Yang, PhD^{1,2}, Nirmala Bhoo-Pathy, PhD³, Judith S. Brand, PhD⁴, Elham Hedayati, PhD⁵, Felix Grassmann, PhD^{2,6}, Erwei Zeng, MSc², Jonas Bergh, PhD^{5,7,8}, Weiwei Bian, MSc², Jonas F. Ludvigsson, PhD^{2,9}, Per Hall, PhD^{2,10}, Kamila Czene, PhD²

Author affiliations:

1. Department of Epidemiology and Health Statistics, School of Public Health, Fujian Medical University, 350122, Fuzhou, China
2. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Nobels Väg 12A, 171 77 Stockholm, Sweden.
3. Centre for Epidemiology and Evidence-Based Practice, Faculty of Medicine, University of Malaya, 50603 Lembah Pantai, Kuala Lumpur, Malaysia.
4. Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, 70185, Örebro, Sweden.
5. Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
6. Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK
7. Breast Cancer Center, Karolinska University Hospital, Stockholm, Sweden.
8. Karolinska Comprehensive Cancer Center, Stockholm, Sweden
9. Department of Pediatrics, Örebro University Hospital, 70185 Örebro, Sweden
10. Department of Oncology, South General Hospital, 118 83 Stockholm, Sweden

***Corresponding author:**

Haomin Yang, PhD. Email: haomin.yang@ki.se; Phone: 0086-13581540402; Fax: 0086-591-22862510. Department of Epidemiology and Health Statistics, School of Public Health, Fujian Medical University, Xuefu North Road 1, University Town, Fuzhou, China.

26 **Tables: 3; Figures: 1; Supplementary Tables: 4**

27 **References: 44**

28 **Word count:2744**

29 **Running title:** Risk of heart diseases following breast cancer

30

31 **LIST OF ABBREVIATIONS**

32 ICD: International Classification of Diseases

33 CI: confidence intervals

34 HR: hazard ratio

35 CCI: Charlson Comorbidity Index

36

37 **ABSTRACT**

38 **BACKGROUND:** There is a rising concern about treatment-associated cardiotoxicities in breast
39 cancer patients.

40 **OBJECTIVES:** This study aimed to determine the time- and treatment-specific incidence of
41 arrhythmia, heart failure and ischemic heart disease in women diagnosed with breast cancer.

42 **METHODS:** A register-based matched cohort study was conducted including 8338 breast cancer
43 patients diagnosed from 2001-2008 in the Stockholm-Gotland region and followed-up until 2017.
44 Overall and time dependent risks of arrhythmia, ischemic heart disease and heart failure in breast
45 cancer patients were assessed using flexible parametric models as compared to matched controls
46 from general population. Treatment-specific effects were estimated in breast cancer patients using
47 Cox model.

48 **RESULTS:** During a median follow-up of 10.8 years, the hazard ratios for arrhythmia, heart failure
49 and ischemic heart disease, were 1.27 (95% CI = 1.18-1.37), 1.38 (95% CI = 1.23-1.55), and 0.93
50 (95% CI = 0.84-1.03), respectively. Time-dependent analyses revealed long-term increased risks of
51 arrhythmia, and heart failure in breast cancer patients compared to matched controls. The risk of
52 ischemic heart disease was only elevated in the first year after cancer diagnosis. Trastuzumab and
53 anthracyclines were associated with increased risk of heart failure. Aromatase inhibitors, but not
54 tamoxifen, were associated with risk of ischemic heart disease. No increased risk of heart disease
55 was identified following loco-regional radiotherapy.

56 **CONCLUSIONS:** Administration of systemic adjuvant therapies appear to be associated with
57 increased risks of heart disease. The risk estimates observed in this study may serve as reference to
58 aid adjuvant therapy decision-making and patient counseling in oncology practices.

59

INTRODUCTION

The use of adjuvant systemic therapies at least halves the risk of dying from breast cancer (Early Breast Cancer Trialists' Collaborative, 2005, 2012; Early Breast Cancer Trialists' Collaborative et al., 2015; Goldvaser et al., 2019; Gray et al., 2019). Nowadays, 80% of the breast cancer patients survive for at least 10 years and many will become long-term survivors (Colzani et al., 2011a). There are, however, concerns about therapy associated late adverse health effects, including cardiovascular events (Khoury et al., 2012). Use of common (neo-) adjuvant therapies for breast cancer have been associated with an increased risk of heart diseases including heart failure, arrhythmias and ischemic heart disease (Darby et al., 2013; Doyle, Neugut, Jacobson, Grann, & Hershman, 2005; Harris et al., 2006; Hooning et al., 2007; Pinder, Duan, Goodwin, Hortobagyi, & Giordano, 2007; C. Taylor et al., 2017; Yeh & Bickford, 2009). However, this evidence mostly comes from studies focusing on specific subgroups of patients based on age, cancer stage or treatment regimen.

Although the benefits of radiotherapy far outweigh the risk of heart diseases, some studies have found increased incidence of and mortality due to heart disease in women subjected to modern doses of adjuvant radiotherapy (Darby et al., 2013; C. Taylor et al., 2017). Knowledge on cardiotoxic effects of anthracycline-based chemotherapy regimens have led to lowering of doses and less use of bolus injections to reduce peak concentrations of anthracyclines (Foukakis et al., 2016), but it is estimated that the risk of heart failure associated with anthracyclines remains increased for standard low-dose group as compared to non-users (Chung et al., 2020). While trastuzumab has been shown to reduce the risk of breast cancer mortality at 11 years of follow-up (Cameron et al., 2017), evidence on its cardiotoxicity is conflicting (Bowles et al., 2012; Papakonstantinou et al., 2020). In addition, recent evidence suggests that use of aromatase inhibitors in women with hormone receptor positive breast cancer may increase the risk of heart

failure, compared to tamoxifen (Khosrow-Khavar, Filion, Bouganim, Suissa, & Azoulay, 2020).

Risk assessment of immediate and later occurring heart disease events following breast cancer is important for the planning of cardiac surveillance programs and possible prophylactic pharmacotherapy. Here, we report the risks of heart diseases in a cohort representative of the general breast cancer population with long-term follow-up. We specifically aimed to assess risks of heart diseases by time since diagnosis, and according to adjuvant treatments.

Materials and Methods

Breast cancer cohort

This study took advantage of the Stockholm-Gotland Breast Cancer Register comprising all women diagnosed with primary invasive breast cancer between 2001 and 2008 in the Stockholm-Gotland region. The Stockholm-Gotland Breast Cancer Register has about 99% completeness and provides detailed information on tumor and treatment characteristics, as well as routine follow-up on locoregional recurrences and distant metastases (Colzani et al., 2011b; Wigertz et al., 2012). We included all patients diagnosed with non-metastatic disease (stages I-III) at age 25 to 75 years (N = 8338). To compare the risk of heart diseases after breast cancer, we randomly sampled up to 10 women from the general female population in Stockholm-Gotland region matched on year of birth and whether they had history of the three heart diseases (Supplementary Figure 1). We performed the matching procedure for these three heart diseases separately. Each reference individual was alive and free of breast cancer on the date of the matched patient's diagnosis of breast cancer (the index date).

The matched cohort was linked through the unique personal identity number to the Swedish Cancer Register, Patient Register, Cause of Death Register and Migration Register, and follow-up started from the index date until the date of heart disease diagnosis, emigration, death, breast cancer relapse or end of follow-up (31 December 2017), whichever occurred first. We also performed

linkage with the Prescribed Drug Register which contains data on all drugs dispensed from Swedish pharmacies from July 2005 onward to validate the use of hormone therapy. Detailed description of the breast cancer cohort can be found elsewhere (Holm et al., 2016).

The study was approved by the Regional Ethical Review Board in Stockholm.

Heart diseases

We identified the following heart diseases according to relevant ICD (International Classification of Disease) codes in the Swedish Patient Register and the Cause of Death Register (Supplementary Table 1): heart failure (ICD-10: I50, ICD-9: 428A, 428B, 428X), arrhythmias (ICD-10: I47-I49, ICD-9: 427), and ischemic heart disease (ICD-10: I20-I25, ICD-9: 410-414). We included both inpatient and outpatient diagnoses, as well as cause of death records in our outcome definition, except for myocardial infarction, which was based on inpatient and cause of death records solely. To ensure specificity of the outcomes studied, only primary, and not underlying, diagnoses were considered for analyses.

Breast cancer treatment specifics

We extracted the treatment data from the Stockholm-Gotland Breast Cancer Register. Because ~90% of HER-2 positive cancers were treated with trastuzumab between 2005 and 2008 in the Stockholm-Gotland region, HER-2 positivity was used as a proxy when no registry data on trastuzumab was available during this time period. Data on adjuvant endocrine therapy was verified against the Prescribed Drug Register and categorized into tamoxifen and / or aromatase inhibitor (AI) use. Since radiotherapy to the left breast has, in particular, been implicated in heart complications, radiotherapy was categorized according to tumor laterality (left vs. right). Bilateral tumors were coded as receiving left-sided radiotherapy in this analysis. Chemotherapy was coded as anthracycline-based, anthracycline plus taxane-based, cyclophosphamide, methotrexate and fluorouracil (CMF)-based regimens, or unknown/unspecified.

Covariates

The Stockholm Breast Cancer Register contains data on date of diagnosis, menopausal status at diagnosis and type of surgery (breast conserving surgery vs. mastectomy). Tumor characteristics were also retrieved from this register, including tumor size (T), regional lymph node involvement (N) and presence of metastases (M), all from pathology records and summarized in TNM stage as defined according to the American Joint Committee on Cancer ("American Joint Committee on Cancer. Breast Cancer Staging. 7th Edition. ,"). Information on inpatient comorbidities at diagnosis was extracted through the Swedish Patient Register and summarized into the Charlson Comorbidity Index (CCI) score, a widely used method for classifying chronic comorbid conditions (Charlson, Pompei, Ales, & MacKenzie, 1987). To account for the potential confounding effect from tobacco abuse, chronic pulmonary disease, and hypertension in the associations, we further identified associated diagnoses before cancer using ICD codes from the patient register. (Supplementary Table 1)

Statistical analyses

We compared the risk of heart diseases in breast cancer patients with that observed in the matched cohort, using flexible parametric model (FPM), overall and stratified by history of respective heart disease and time since diagnosis. We further plotted time-dependent hazard ratios using FPM. The FPM is similar to the Cox proportional hazards model in that it provides a HR as measure of association. The key advantage of FPM is that non-proportional hazards can easily be fitted by adding a spline for the interaction with time. Kaplan-Meier curves were used to assess the cumulative incidences of heart diseases in breast cancer patients and matched reference individuals.

Next, we studied the association of adjuvant breast cancer therapy with heart disease risk in breast cancer patients using Cox proportional hazards models. We adjusted these analyses for age and year of diagnosis (model 1), and additionally for menopausal status at diagnosis,

cancer stage, type of surgery, CCI score, history of heart disease, hypertension, chronic pulmonary disease and tobacco abuse. All treatment specific models were mutually adjusted for adjuvant therapies. Taking the possible selection bias in administration of radiotherapy into consideration, the analysis for radiotherapy only included patients receiving radiotherapy, making a comparison between left-sided and right-sided breast cancer (Wadsten et al., 2018). Missing indicators were included for the analysis of these covariates in the model. To investigate the robustness of treatment specific associations, a sensitivity analysis was performed excluding breast cancer patients with a history of heart disease. To explore the potential time dependent effect of treatment, we separated the analysis according to different follow-up periods, within 10 years after breast cancer diagnosis and beyond, respectively.

All statistical analyses were performed using STATA version 15.1.

RESULTS

Descriptive characteristics of the study population are described in Table 1. The median age at breast cancer diagnosis was 59 years, with 75% of patients aged less than 65 years (Table 1). Approximately 40% of all patients received adjuvant chemotherapy, with anthracycline-based regimens being most frequently administered. Endocrine therapy was received by more than 80% of patients (constituting mainly of tamoxifen). Of all patients diagnosed between mid-2005 and 2008, 13% were coded as receivers of trastuzumab.

Over a median follow-up of 10.8 years (interquartile range = 6.5 years) arrhythmias were the most frequently reported heart disease (n = 677), followed by ischemic heart disease (n = 384) and heart failure (n = 306). The cumulative incidence of arrhythmias, ischemic heart disease and heart failure in the cohort was 12.10%, 6.55% and 5.59% after 15 years of follow-up, respectively (Supplementary Figure 2 and Supplementary Table 2).

Table 1. Descriptive characteristics of the study population.

Characteristics	overall (N = 8338)
Year of diagnosis. % (N)	
2001-2002	25.8 (2148)
2003-2004	24.3 (2027)
2005-2006	25.8 (2147)
2007-2008	24.2 (2016)
Age at diagnosis. % (N)	
< 50 years	22.3 (1857)
50-65 years	50.8 (4239)
>65 years	26.9 (2242)
Menopausal status. % (N)	
Premenopausal	29.4 (2311)
Postmenopausal	70.6 (5539)
Missing (N)	488
Stage. % (N)	
Stage I	48.1 (3826)
Stage II	39.4 (3131)
Stage III	12.5 (996)
Missing (N)	385
Comorbidity. % (N)	
None	88.6 (7385)
1	6.2 (514)
≥ 2	5.3 (439)
History of Arrhythmia. % (N)	
No	97.9 (8161)
Yes	2.1 (177)
History of Heart Failure. % (N)	
No	99.5 (8295)
Yes	0.5 (43)
History of Ischemic Heart Disease. % (N)	
No	98.1 (8176)
Yes	1.9 (162)
Surgery. % (N)	
No	1.1 (90)
Yes, breast-conserving	60.3 (5014)
Yes, mastectomy	38.6 (3205)
Missing (N)	29
Radiotherapy. % (N)	
No, right-sided	11.4 (928)
No, left-sided	11.8 (954)
Yes, right-sided	37.7 (3057)
Yes, left-sided	39.1 (3173)
Missing (N)	226
Chemotherapy. % (N)	
No	59.1 (4830)
Yes	40.9 (3343)
Missing (N)	165
Hormone therapy. % (N)	
No	18.0 (1472)
Yes, tamoxifen	53.6 (4380)
Yes, aromatase inhibitors	20.3 (1657)
Yes, type unknown	8.1 (664)
Missing (N)	165
Trastuzumab therapy, % (N) *	
No	87.6 (2277)
Yes	12.4 (323)
Missing (N)	1565

Missingness on individual variables is less than 5%, except for menopausal status (5.9%, N = 488). Treatment-specific analysis of trastuzumab was restricted to patients diagnosed between 2005 and 2008 (missingness = 37.6%, N = 1565).

Overall, breast cancer patients experienced a 27% increased risk (HR = 1.27; 95% CI = 1.18-1.37) of developing arrhythmia, and a 38% increased risk of heart failure (HR=1.38; 95% CI = 1.23-1.55) compared to matched reference individuals from general population, while the risk of ischemic heart disease was not increased (HR = 0.93; 95% CI = 0.84-1.03) (Table 2). Hazard ratios of for arrhythmias, ischemic heart disease and heart failure were not notably different in women with or without a previous diagnosis of these respective heart diseases.

Analyses by time since diagnosis revealed a short-term increase in risks of arrhythmia and heart failure (Table 2). An elevated risk of ischemic heart disease was observed in the first year after diagnosis (HR = 1.48; 95% CI = 1.14-1.91), followed by a decline with increasing follow-up time. Interestingly, increased risks for arrhythmia and heart failure were noted beyond 10 years (Table 2, Figure 1).

Table 2. Hazard for heart diseases in breast cancer patients compared to the matched cohort.

	Arrhythmia		Heart Failure		Ischemic Heart Disease	
	No.	HR (95% CI)	No.	HR (95% CI)	No.	HR (95% CI)
Overall	677	1.27 (1.18-1.37)	306	1.38 (1.23-1.55)	384	0.93 (0.84-1.03)
Corresponding disease history						
No	585	1.28 (1.18-1.39)	286	1.39 (1.23-1.57)	321	0.91 (0.81-1.01)
Yes	92	1.30 (1.04-1.61)	20	1.25 (0.77-2.05)	63	1.04 (0.80-1.36)
Time since diagnosis						
<1 year	109	2.21 (1.81-2.70)	37	2.71 (1.88-3.91)	65	1.48 (1.14-1.91)
1-2 years	48	1.10 (0.82-1.48)	24	1.94 (1.26-3.01)	41	0.97 (0.70-1.34)
2-5 years	123	1.03 (0.86-1.24)	52	1.31 (0.99-1.74)	94	0.92 (0.75-1.13)
5-10 years	226	1.13 (0.99-1.30)	95	1.13 (0.91-1.38)	121	0.84 (0.70-1.00)
10-17 years	171	1.42 (1.22-1.66)	98	1.38 (1.12-1.69)	63	0.79 (0.61-1.01)

* Abbreviations: No.=number of cases. HR=hazard ratio. CI = confidence interval. The HRs are estimated using flexible parametric model and conditioned on matching criteria (year of birth and history of respective heart disease). In all models, time since index date was the underlying time scale and a restricted cubic spline with four internal and two boundary knots (five degrees of freedom) placed at quintiles of the event times, was used for the baseline hazard.

Figure 1. Time dependent hazard ratio of heart diseases in breast cancer patients comparing to age-matched women.

In all models, time since index date was the underlying time scale and a restricted cubic spline with four internal and two boundary knots (five degrees of freedom) placed at quintiles of the event times, was used for the baseline hazard. Time-dependent effects were modelled by adding interaction terms with time using a second spline with three degrees of freedom.

Patients treated with chemotherapy and trastuzumab had an increased risk of heart failure compared to patients not receiving these treatments (for patients receiving anthracyclines-based chemotherapy, HR=1.99, 95% CI=1.38-2.85; for patients receiving trastuzumab, HR=2.04, 95%CI=1.10-3.80) (Table 3). The risk of heart failure in patients receiving anthracyclines ever persisted for 10 years beyond the diagnosis of breast cancer (HR= 2.31, 95%CI=1.21-4.43, supplementary table 3). Receipt of aromatase inhibitors was marginally associated with risk of ischemic heart disease (HR=1.42, 95%CI=1.00-2.01 compared to patients without hormonal therapy), but not with risk of heart failure or arrhythmias (Table 3). A direct comparison between left-sided and right-sided radiotherapy, showed no evidence of an association of radiotherapy with heart disease except for a somewhat increased risk of ischemic heart disease in women with left sided breast cancer, particularly after 10 years after cancer diagnosis, although not statistically significant (HR= 1.14, 95%CI=0.89-1.46; HR for the risk beyond 10 years=1.32, 95%CI=0.74-2.36). Sensitivity analyses excluding breast cancer patients with a previous history of heart disease only slightly changed the point estimates of the treatment effects but not the inferences (Supplementary Table 4).

233 **Table 3.** Hazard ratios for heart diseases by different adjuvant therapies

Treatment variables	Total No.	HR (95% CI) for Arrhythmia			HR (95% CI) for heart failure			HR (95% CI) for ischemic heart disease		
		N	Model1	Model2	N	Model1	Model2	N	Model 1	Model2
Radiotherapy										
Right-sided	3057	251	REF (1.00)	REF (1.00)	102	REF (1.00)	REF (1.00)	121	REF (1.00)	REF (1.00)
Left-sided	3173	244	0.93 (0.78-1.11)	0.91 (0.76-1.08)	104	0.96 (0.73-1.26)	0.99 (0.76-1.31)	141	1.11 (0.87-1.42)	1.14 (0.89-1.46)
Missing	226	13	-	-	14	-	-	9	-	-
Chemotherapy										
No	4830	454	REF (1.00)	REF (1.00)	176	REF (1.00)	REF (1.00)	262	REF (1.00)	REF (1.00)
Anthracyclines-based	1458	96	1.12 (0.90-1.41)	0.99 (0.77-1.28)	58	2.26 (1.66-3.08)	1.99 (1.38-2.85)	50	1.11 (0.81-1.52)	1.10 (0.78-1.57)
Anthracyclines+Taxanes	295	10	0.88 (0.47-1.67)	0.75 (0.39-1.45)	13	5.55 (3.05-10.08)	4.39 (2.31-8.37)	7	1.31 (0.60-2.82)	1.20 (0.54-2.67)
CMF	108	13	1.62 (0.93-2.82)	1.39 (0.79-2.47)	5	1.57 (0.64-3.84)	1.12 (0.45-2.79)	5	1.01 (0.41-2.45)	0.69 (0.28-1.70)
Type unknown	1482	93	1.21 (0.96-1.53)	1.15 (0.87-1.51)	43	1.87 (1.32-2.66)	1.65 (1.09-2.49)	55	1.38 (1.02-1.87)	1.44 (1.01-2.07)
Missing	165	11	-	-	11	-	-	5	-	-
Hormone therapy										
No	1472	101	REF (1.00)	REF (1.00)	55	REF (1.00)	REF (1.00)	57	REF (1.00)	REF (1.00)
Tamoxifen	4380	345	0.94 (0.75-1.17)	1.03 (0.81-1.31)	125	0.61 (0.45-0.84)	0.84 (0.60-1.18)	168	0.79 (0.58-1.07)	0.90 (0.65-1.24)
Aromatase inhibitors	1657	159	1.16 (0.90-1.51)	1.09 (0.83-1.43)	82	1.13 (0.79-1.62)	1.08 (0.74-1.57)	109	1.41 (1.00-1.97)	1.42 (1.00-2.01)
Type unknown	664	61	0.85 (0.61-1.19)	0.91 (0.65-1.28)	33	0.72 (0.46-1.13)	0.95 (0.59-1.51)	45	1.05 (0.70-1.58)	1.25 (0.82-1.89)
Missing	165	11	-	-	11	-	-	5	-	-
Trastuzumab *										
No	2277	160	REF (1.00)	REF (1.00)	52	REF (1.00)	REF (1.00)	81	REF (1.00)	REF (1.00)
Yes	323	21	1.17 (0.74-1.84)	1.42 (0.87-2.31)	15	2.69 (1.51-4.80)	2.04 (1.10-3.80)	15	1.63 (0.94-2.83)	1.48 (0.82-2.67)
Missing	1565	115	-	-	53	-	-	63	-	-

234 Abbreviations: Total No. refers to the total number of patients. N events refers to the number of observed cases. HR = hazard ratio; CI = confidence interval. Hazard ratios are
235 estimated from Cox proportional hazards models with time since diagnosis as underlying time scale. Hazard ratios for model 1 are adjusted for age and calendar period. Hazard
236 ratios for model 2 are multivariable adjusted including age at diagnosis (years), year of diagnosis (2001/2002, 2003/2004, 2005/2006, 2007/2008), menopausal status
237 (premenopausal, postmenopausal, unknown), Charlson comorbidity index (0, 1, ≥ 2), clinical stage (I, II, III, unknown), type of surgery (no, partial mastectomy, total mastectomy,
238 unknown), history of the specific heart disease, hypertension, chronic pulmonary disease and tobacco abuse, and all treatment variables listed in the table. * Treatment-specific
239 analysis of trastuzumab was restricted to patients diagnosed between 2005 and 2008.

DISCUSSION

In a population-based setting, we demonstrated that the incidence of heart disease in breast cancer patients was significantly higher than the incidence observed in matched reference individuals from the general population. The risks of arrhythmia and heart failure were increased even beyond 15 years after diagnosis. Receipt of trastuzumab, as well as administration of anthracycline +/- taxane-based regimens were independently associated with an increased risk of heart failure, while aromatase inhibitor therapy was associated with an increased risk of ischemic heart disease.

We found an increased risk of arrhythmia and heart failure in breast cancer patients as compared with the matched reference individuals from the general population, which is similar to the risk of heart failure reported by a previous Dutch study (Hoening et al., 2007), indicating the generalizability of our findings within European countries. In the present study, we further found similar magnitude HRs estimates in patients with and without a previous diagnosis of heart disease, suggesting no effect modification by disease history.

Analysis by time since diagnosis from the current study revealed long-term increased risks of arrhythmia and heart failure following breast cancer. The long-term increased risk of heart failure potentially reflects the profound cardiotoxic effect of anthracyclines, as we found increased risk of heart failure in patients treated with anthracyclines beyond 10 years after cancer diagnosis. As the long-term risk was observed for heart failure but not ischemic heart disease, we hypothesized that the cardiotoxic effect of chemotherapy was mainly on the myocardium but not the cardiac vessels. The finding that risk of ischemic heart disease in breast cancer patients may be shortly elevated after diagnosis, but diminish over time is not unexpected, considering the emotional distress of dealing with a new cancer diagnosis in the patients, which may lead to higher short-term rates of ischemic heart disease (Fang et al., 2012; Schoormans, Pedersen, Dalton, Rottmann, & van de Poll-Franse, 2016).

The findings that administration of anthracycline +/- taxanes, as well as trastuzumab are associated with increased risks of heart failure are in agreement with previous observational studies (Bowles et al., 2012; Chavez-MacGregor et al., 2013; Doyle et al., 2005; Du et al., 2009; Goldhar et al., 2016; Thavendiranathan et al., 2016) and clinical trials (Chen et al., 2011) in specific subgroups of breast cancer patients. While (poly)chemotherapy is thought to lead to heart failure through a plethora of mechanisms that damage cardiomyocytes (Yeh & Bickford, 2009), taxanes may also interrupt the metabolism and excretion of anthracyclines, hence accentuating their toxicity (Bird & Swain, 2008). Inhibition of the HER2 receptors in myocytes, which regulates cell development and growth may largely explain the cardiotoxicity caused by trastuzumab (Yeh & Bickford, 2009).

Population-based estimates of incidence of ischemic heart disease following treatment with aromatase inhibitors have not been extensively reported in the literature (Matthews et al., 2018). Abdel-Qadir, *et al* also found an increased risk of myocardial infarction in patients treated with aromatase inhibitors, as compared to those treated with tamoxifen (Abdel-Qadir et al., 2016). It has been posited that this apparent increase in risk of ischemic heart disease might in fact be attributed to reduced risk of heart disease following tamoxifen treatment (Hackshaw et al., 2011; Rosell et al., 2013). Nonetheless, given that in the present study, an increased risk of ischemic heart disease was observed in patients treated with aromatase inhibitors compared to patients not receiving hormone treatment, prior hypothesis that this observation is explained by the protective effect of tamoxifen is not fully correct.

While several previous studies have shown that radiotherapy for breast cancer increase the risk of ischemic heart disease and heart failure (Darby et al., 2013; Harris et al., 2006; Pinder et al., 2007), some studies, particularly those including patients diagnosed in recent decades, have not seen such increase (Boekel et al., 2014; Wadsten et al., 2018; Wennstig et al., 2020). Indeed, the time trends of heart dose improvement and the use of modern heart dose sparing

techniques, together with individualized doses of therapy, may result in lower doses of radiation to the heart (C. Taylor et al., 2017; C. W. Taylor & Kirby, 2015; C. W. Taylor et al., 2009). Another reason for inconsistent results in the literature could be that patients with a left sided breast cancer who are susceptible to cardiovascular disease are less likely to be selected for radiotherapy (C. W. Taylor & Kirby, 2015). Therefore, in our study, we compared risk of ischemic heart disease in patients treated with radiotherapy for left-sided to those treated for right-sided breast cancer. We found slightly increased non-significant risk of ischemic heart disease, this risk appeared (as expected) more pronounced in the follow-up period after 10 years. Overall, our results indicate only small risk of heart disease due to radiotherapy in women treated in Sweden after year 2000.

A major strength of our study is that we were able to investigate risks of heart disease by time since diagnosis and adjuvant treatment. The risk estimates presented in this study therefore provide an insight into the short-term and long-term unintended effects of adjuvant breast cancer therapy in routine clinical practice. Notably, all breast cancer patients were followed-up for a relatively long period. The population-based nature of the study and linkage to registry-based data further minimized the risk of selection and information biases.

We acknowledge several limitations. The Swedish Patient Register has high validity for heart failure, arrhythmia and ischemic heart disease (with positive predictive value between 88%-98%) (Hammar et al., 2001; Ludvigsson et al., 2011), but some misclassification of heart diseases may have occurred. We further tried to reduce the likelihood of misclassification by analysing main diagnoses only. Secondly, we did not have complete data on trastuzumab during the study period and relied on HER-2 status as proxy, which may have resulted in some misclassification. The numbers of heart disease after trastuzumab and taxane were also relatively small in our study, and might have resulted in limited power or chance finding when identifying an association between trastuzumab/taxane and the relevant cardiac events. Besides,

the Stockholm-Gotland Breast Cancer Register only records intended treatment with radiotherapy and chemotherapy, not whether patients were actually administrated with these therapies. Finally, it should be noted that cancer patients are subject to increased medical surveillance, especially in the initial period after diagnosis. This could explain the increased rates of heart disease events especially within the first year of follow-up, although psychological distress following recent diagnosis with cancer represents an alternative plausible explanation for this observation (Fang et al., 2012; Schoormans et al., 2016).

Through this study, we demonstrate that compared to the general population, women with breast cancer are associated with significantly increased risks of cardiovascular events including heart failure and arrhythmia. The short term risk of ischemic heart disease diminished after 1 year post diagnosis. The increased risk of arrhythmia and heart failure however appears to persist long-term, beyond the first decade after diagnosis. The risk estimates observed in this study may serve as reference to aid adjuvant therapy decision-making and patient counselling in oncology practices.

DECLARATIONS:

Competing interests: The authors declare no competing interest.

Ethics approval and consent to participate

The study was approved by the Regional Ethical Review Board in Stockholm (Dnr 2009/254-31/4).

Author contributions:

HY had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. KC, NBP and HY conceived and designed the

study. All authors acquired, analyzed, or interpreted the data. HY and NBP drafted the manuscript. All authors critically revised the manuscript for important intellectual content. HY performed the statistical analysis. KC, NBP and HY obtained the funding. All authors read and approved the final manuscript.

Funding

This work was supported by the Swedish Research Council [grant no: 2018-02547]; Swedish Cancer Society [grant no: CAN-19-0266] and FORTE [grant no: 2016-00081]. HY was supported by Startup Fund for high-level talents of Fujian Medical University [grant no: XRCZX2020007] and Startup Fund for scientific research, Fujian Medical University [grant no: 2019QH1002]. NBP was supported by the University of Malaya Impact-Oriented Interdisciplinary Research Grant Programme [grant no: IIRG006C-19HWB]. WB was partly supported by China Scholarship council. Dr Ludvigsson coordinates a study on behalf of the Swedish IBD quality register (SWIBREG), which has received funding from Janssen corporation. The funders had no role in the study design, data collection, analyses, data interpretation, writing the manuscript, or in the decision to submit the manuscript for publication.

Acknowledgements

Not applicable.

Availability of data and materials

The register-based cohort datasets linked and analyzed in the current study are not publicly available due to Swedish law, but are available by applying through the Swedish National Board of Health and Welfare and Statistics Sweden. Detailed information on data application can be found using the following links <https://bestalladata.socialstyrelsen.se/data-for-forskning/> and <https://www.scb.se/vara-tjanster/bestalla-mikrodata/>.

Consent to publish

All authors approved the manuscript and consented to its publication.

Authors' information

Not applicable.

REFERENCES

- Abdel-Qadir, H., Amir, E., Fischer, H. D., Fu, L., Austin, P. C., Harvey, P. J., . . . Anderson, G. M. (2016). The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer. *European journal of cancer*, 68, 11-21. doi:10.1016/j.ejca.2016.08.022
- American Joint Committee on Cancer. Breast Cancer Staging. 7th Edition. . Retrieved from Available at <https://cancerstaging.org/references-tools/quickreferences/Documents/BreastLarge.pdf>
- Bird, B. R., & Swain, S. M. (2008). Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. *Clin Cancer Res*, 14(1), 14-24. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/18172247>. doi:10.1158/1078-0432.CCR-07-1033
- Boekel, N. B., Schaapveld, M., Gietema, J. A., Rutgers, E. J., Versteegh, M. I., Visser, O., . . . van Leeuwen, F. E. (2014). Cardiovascular morbidity and mortality after treatment for ductal carcinoma in situ of the breast. *Journal of the National Cancer Institute*, 106(8). Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/25128694>. doi:10.1093/jnci/dju156
- Bowles, E. J., Wellman, R., Feigelson, H. S., Onitilo, A. A., Freedman, A. N., Delate, T., . . . Pharmacovigilance Study, T. (2012). Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. *Journal of the National Cancer Institute*, 104(17), 1293-1305. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/22949432>. doi:10.1093/jnci/djs317
- Cameron, D., Piccart-Gebhart, M. J., Gelber, R. D., Procter, M., Goldhirsch, A., de Azambuja, E., . . . Herceptin Adjuvant Trial Study, T. (2017). 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. *Lancet*, 389(10075), 1195-1205. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/28215665>. doi:10.1016/S0140-6736(16)32616-2
- Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987). A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*, 40(5), 373-383. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/3558716>. doi:10.1016/0021-9681(87)90171-8
- Chavez-MacGregor, M., Zhang, N., Buchholz, T. A., Zhang, Y., Niu, J., Elting, L., . . . Giordano, S. H. (2013). Trastuzumab-related cardiotoxicity among older patients with breast cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 31(33), 4222-4228. Retrieved from <https://pubmed.ncbi.nlm.nih.gov/24127446> <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3821011/>. doi:10.1200/JCO.2013.48.7884
- Chen, T., Xu, T., Li, Y., Liang, C., Chen, J., Lu, Y., . . . Wu, S. (2011). Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. *Cancer Treat Rev*, 37(4), 312-320. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/20952131>. doi:10.1016/j.ctrv.2010.09.001
- Chung, I. Y., Lee, J. W., Moon, H.-G., Shin, K. H., Han, W., Son, B. H., . . . Noh, D.-Y. (2020). Effect of standard low-dose anthracycline chemotherapy on late congestive heart failure in breast cancer survivors aged between 50 and 59 at diagnosis: A nationwide study. *The Breast*, 53, 125-129. Retrieved from

- 415 <http://www.sciencedirect.com/science/article/pii/S096097762030148X>.
- 416 doi:<https://doi.org/10.1016/j.breast.2020.07.006>
- 417 Colzani, E., Liljegren, A., Johansson, A. L., Adolfsson, J., Hellborg, H., Hall, P. F., & Czene, K. (2011a).
- 418 Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis,
- 419 age, and tumor characteristics. *Journal of clinical oncology : official journal of the American*
- 420 *Society of Clinical Oncology*, 29(30), 4014-4021. Retrieved from
- 421 <http://www.ncbi.nlm.nih.gov/pubmed/21911717>. doi:10.1200/JCO.2010.32.6462
- 422 Colzani, E., Liljegren, A., Johansson, A. L., Adolfsson, J., Hellborg, H., Hall, P. F., & Czene, K. (2011b).
- 423 Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis,
- 424 age, and tumor characteristics. *Journal of clinical oncology : official journal of the American*
- 425 *Society of Clinical Oncology*, 29(30), 4014-4021. Retrieved from
- 426 <http://www.ncbi.nlm.nih.gov/pubmed/21911717>
- 427 <http://jco.ascopubs.org/content/29/30/4014.full.pdf>. doi:10.1200/JCO.2010.32.6462
- 428 Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Bronnum, D., . . . Hall, P.
- 429 (2013). Risk of ischemic heart disease in women after radiotherapy for breast cancer. *N Engl J*
- 430 *Med*, 368(11), 987-998. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/23484825>.
- 431 doi:10.1056/NEJMoa1209825
- 432 Doyle, J. J., Neugut, A. I., Jacobson, J. S., Grann, V. R., & Hershman, D. L. (2005). Chemotherapy and
- 433 cardiotoxicity in older breast cancer patients: a population-based study. *Journal of clinical*
- 434 *oncology : official journal of the American Society of Clinical Oncology*, 23(34), 8597-8605.
- 435 Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/16314622>.
- 436 doi:10.1200/JCO.2005.02.5841
- 437 Du, X. L., Xia, R., Liu, C. C., Cormier, J. N., Xing, Y., Hardy, D., . . . Burau, K. (2009). Cardiac toxicity
- 438 associated with anthracycline-containing chemotherapy in older women with breast cancer.
- 439 *Cancer*, 115(22), 5296-5308. Retrieved from
- 440 <https://www.ncbi.nlm.nih.gov/pubmed/19672997>. doi:10.1002/cncr.24621
- 441 Early Breast Cancer Trialists' Collaborative, G. (2005). Effects of chemotherapy and hormonal therapy
- 442 for early breast cancer on recurrence and 15-year survival: an overview of the randomised
- 443 trials. *Lancet*, 365(9472), 1687-1717. Retrieved from
- 444 <http://www.ncbi.nlm.nih.gov/pubmed/15894097>. doi:10.1016/S0140-6736(05)66544-0
- 445 Early Breast Cancer Trialists' Collaborative, G. (2012). Comparisons between different
- 446 polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome
- 447 among 100 000 women in 123 randomised trials. *The Lancet*, 379(9814), 432-444. Retrieved
- 448 from <http://www.sciencedirect.com/science/article/pii/S0140673611616255>.
- 449 doi:[https://doi.org/10.1016/S0140-6736\(11\)61625-5](https://doi.org/10.1016/S0140-6736(11)61625-5)
- 450 Early Breast Cancer Trialists' Collaborative, G., Dowsett, M., Forbes, J. F., Bradley, R., Ingle, J., Aihara,
- 451 T., . . . Gray, R. (2015). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-
- 452 level meta-analysis of the randomised trials. *Lancet*, 386(10001), 1341-1352. Retrieved from
- 453 <http://www.ncbi.nlm.nih.gov/pubmed/26211827>
- 454 <http://spiral.imperial.ac.uk/bitstream/10044/1/32438/8/1-s2.0-S0140673615610741-main.pdf>.
- 455 doi:10.1016/S0140-6736(15)61074-1
- 456 Fang, F., Fall, K., Mittleman, M. A., Sparen, P., Ye, W., Adami, H. O., & Valdimarsdottir, U. (2012).
- 457 Suicide and cardiovascular death after a cancer diagnosis. *N Engl J Med*, 366(14), 1310-1318.
- 458 Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/22475594>
- 459 <http://www.nejm.org/doi/pdf/10.1056/NEJMoa1110307>. doi:10.1056/NEJMoa1110307
- 460 Foukakis, T., von Minckwitz, G., Bengtsson, N. O., Brandberg, Y., Wallberg, B., Fornander, T., . . .
- 461 Colorectal Cancer Study, G. (2016). Effect of Tailored Dose-Dense Chemotherapy vs Standard
- 462 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-
- 463 Risk Early Breast Cancer: A Randomized Clinical Trial. *JAMA*, 316(18), 1888-1896. Retrieved
- 464 from <https://www.ncbi.nlm.nih.gov/pubmed/27825007>. doi:10.1001/jama.2016.15865
- 465 Goldhar, H. A., Yan, A. T., Ko, D. T., Earle, C. C., Tomlinson, G. A., Trudeau, M. E., . . . Chan, K. K.
- 466 (2016). The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast

Cancer Patients: A Population Study. *Journal of the National Cancer Institute*, 108(1). Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/26476433>. doi:10.1093/jnci/djv301

Goldvaser, H., Korzets, Y., Shepshelovich, D., Yerushalmi, R., Sarfaty, M., Ribnikar, D., . . . Amir, E. (2019). Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis. *JNCI cancer spectrum*, 3(2), pkz033-pkz033. Retrieved from <https://pubmed.ncbi.nlm.nih.gov/31360906> <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649709/>. doi:10.1093/jncics/pkz033

Gray, R., Bradley, R., Braybrooke, J., Liu, Z., Peto, R., Davies, L., . . . Zambetti, M. (2019). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. *The Lancet*, 393(10179), 1440-1452. Retrieved from [https://doi.org/10.1016/S0140-6736\(18\)33137-4](https://doi.org/10.1016/S0140-6736(18)33137-4). doi:10.1016/S0140-6736(18)33137-4

Hackshaw, A., Roughton, M., Forsyth, S., Monson, K., Reczko, K., Sainsbury, R., & Baum, M. (2011). Long-Term Benefits of 5 Years of Tamoxifen: 10-Year Follow-Up of a Large Randomized Trial in Women at Least 50 Years of Age With Early Breast Cancer. *Journal of Clinical Oncology*, 29(13), 1657-1663. Retrieved from <https://ascopubs.org/doi/abs/10.1200/JCO.2010.32.2933>. doi:10.1200/jco.2010.32.2933

Hammar, N., Alfredsson, L., Rosen, M., Spetz, C. L., Kahan, T., & Ysberg, A. S. (2001). A national record linkage to study acute myocardial infarction incidence and case fatality in Sweden. *Int J Epidemiol*, 30 Suppl 1, S30-34. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/11759848>. doi:10.1093/ije/30.suppl_1.s30

Harris, E. E., Correa, C., Hwang, W. T., Liao, J., Litt, H. I., Ferrari, V. A., & Solin, L. J. (2006). Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 24(25), 4100-4106. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/16908933>. doi:10.1200/JCO.2005.05.1037

Holm, J., Li, J., Darabi, H., Eklund, M., Eriksson, M., Humphreys, K., . . . Czene, K. (2016). Associations of Breast Cancer Risk Prediction Tools With Tumor Characteristics and Metastasis. *Journal of Clinical Oncology*, 34(3), 251-258. Retrieved from <https://ascopubs.org/doi/abs/10.1200/JCO.2015.63.0624>. doi:10.1200/jco.2015.63.0624

Hoening, M. J., Botma, A., Aleman, B. M., Baaijens, M. H., Bartelink, H., Klijn, J. G., . . . van Leeuwen, F. E. (2007). Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. *Journal of the National Cancer Institute*, 99(5), 365-375. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/17341728> <http://jnci.oxfordjournals.org/content/99/5/365.full.pdf>. doi:10.1093/jnci/djk064

Khosrow-Khavar, F., Filion, K. B., Bouganim, N., Suissa, S., & Azoulay, L. (2020). Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study. *Circulation*, 141(7), 549-559. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/32065766>. doi:10.1161/CIRCULATIONAHA.119.044750

Khoury, M. G., Douglas, P. S., Mackey, J. R., Martin, M., Scott, J. M., Scherrer-Crosbie, M., & Jones, L. W. (2012). Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. *Circulation*, 126(23), 2749-2763. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/23212997>. doi:10.1161/CIRCULATIONAHA.112.100560

Ludvigsson, J. F., Andersson, E., Ekblom, A., Feychting, M., Kim, J. L., Reuterwall, C., . . . Olausson, P. O. (2011). External review and validation of the Swedish national inpatient register. *BMC Public Health*, 11, 450. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/21658213> <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3142234/pdf/1471-2458-11-450.pdf>. doi:10.1186/1471-2458-11-450

- Matthews, A., Stanway, S., Farmer, R. E., Strongman, H., Thomas, S., Lyon, A. R., . . . Bhaskaran, K. (2018). Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review. *BMJ*, 363. doi:10.1136/BMJ.K3845
- Papakonstantinou, A., Matikas, A., Bengtsson, N. O., Malmstrom, P., Hedayati, E., Steger, G., . . . Bergh, J. (2020). Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trial. *Cancer*, 126(6), 1175-1182. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/31851385>. doi:10.1002/cncr.32653
- Pinder, M. C., Duan, Z., Goodwin, J. S., Hortobagyi, G. N., & Giordano, S. H. (2007). Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 25(25), 3808-3815. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/17664460> <http://jco.ascopubs.org/content/25/25/3808.full.pdf>. doi:10.1200/JCO.2006.10.4976
- Rosell, J., Nordenskjöld, B., Bengtsson, N.-O., Fornander, T., Hatschek, T., Lindman, H., . . . Carstensen, J. (2013). Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up. *Breast cancer research and treatment*, 138(2), 467-473. Retrieved from <https://doi.org/10.1007/s10549-013-2457-6>. doi:10.1007/s10549-013-2457-6
- Schoormans, D., Pedersen, S. S., Dalton, S., Rottmann, N., & van de Poll-Franse, L. (2016). Cardiovascular co-morbidity in cancer patients: the role of psychological distress. *Cardio-Oncology*, 2(1), 9. Retrieved from <https://doi.org/10.1186/s40959-016-0019-x>. doi:10.1186/s40959-016-0019-x
- Taylor, C., Correa, C., Duane, F. K., Aznar, M. C., Anderson, S. J., Bergh, J., . . . Early Breast Cancer Trialists' Collaborative, G. (2017). Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 35(15), 1641-1649. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/28319436>. doi:10.1200/JCO.2016.72.0722
- Taylor, C. W., & Kirby, A. M. (2015). Cardiac Side-effects From Breast Cancer Radiotherapy. *Clin Oncol (R Coll Radiol)*, 27(11), 621-629. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/26133462>. doi:10.1016/j.clon.2015.06.007
- Taylor, C. W., Nisbet, A., McGale, P., Goldman, U., Darby, S. C., Hall, P., & Gagliardi, G. (2009). Cardiac doses from Swedish breast cancer radiotherapy since the 1950s. *Radiother Oncol*, 90(1), 127-135. doi:10.1016/j.radonc.2008.09.029
- Thavendiranathan, P., Abdel-Qadir, H., Fischer, H. D., Camacho, X., Amir, E., Austin, P. C., & Lee, D. S. (2016). Breast Cancer Therapy-Related Cardiac Dysfunction in Adult Women Treated in Routine Clinical Practice: A Population-Based Cohort Study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 34(19), 2239-2246. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/27091709>. doi:10.1200/JCO.2015.65.1505
- Wadsten, C., Wennstig, A. K., Garmo, H., Nilsson, G., Blomqvist, C., Holmberg, L., . . . Sund, M. (2018). Risk of ischemic heart disease after radiotherapy for ductal carcinoma in situ. *Breast cancer research and treatment*, 171(1), 95-101. doi:10.1007/s10549-018-4803-1
- Wennstig, A.-K., Wadsten, C., Garmo, H., Fredriksson, I., Blomqvist, C., Holmberg, L., . . . Sund, M. (2020). Long-term risk of ischemic heart disease after adjuvant radiotherapy in breast cancer: results from a large population-based cohort. *Breast Cancer Research*, 22(1), 10. Retrieved from <https://doi.org/10.1186/s13058-020-1249-2>. doi:10.1186/s13058-020-1249-2
- Wigertz, A., Ahlgren, J., Holmqvist, M., Fornander, T., Adolfsson, J., Lindman, H., . . . Lambe, M. (2012). Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study. *Breast cancer research and treatment*, 133(1), 367-373. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/22286315>. doi:10.1007/s10549-012-1961-4

568 Yeh, E. T., & Bickford, C. L. (2009). Cardiovascular complications of cancer therapy: incidence,
 569 pathogenesis, diagnosis, and management. *J Am Coll Cardiol*, 53(24), 2231-2247. Retrieved
 570 from <https://www.ncbi.nlm.nih.gov/pubmed/19520246>. doi:10.1016/j.jacc.2009.02.050
 571
 572

573

574 **ONLINE SUPPLEMENTARY**

575

576 **Supplementary Table 1.** ICD codes used in the analyses

577 **Supplementary Table 2.** Cumulative incidence estimates of heart diseases in breast cancer

578 patients and age matched controls.

579 **Supplementary Table 3.** Hazard ratios for heart diseases by different adjuvant therapies and

580 time since diagnosis.

581 **Supplementary Table 4.** Hazard ratios for heart diseases by different adjuvant therapies,

582 excluding patients with a history of heart diseases.

583 **Supplementary Figure 1.** Flow chart of the data.

584 **Supplementary Figure 2.** Cumulative incidence of heart disease in breast cancer patients and matched

585 women.

586 Kaplan-Meier estimates of the cumulative risk of heart disease by time since diagnosis, in breast cancer

587 patients and matched women from the general population. BC: breast cancer; REF: reference women in

588 the matched controls from the general population; No.: number.

Supplementary Table 1. ICD codes used in the analyses.

Disease codes	ICD-10	ICD-9
Arrhythmia	I47, I48, I49	427
Atrial fibrillation	I48	427D
Tachycardia and other cardiac arrhythmias	I47, I49	427A-C, 427E-J
Heart failure	I50	428A, 428B, 428X
Ischemic heart disease	I20-I25	410-414
Myocardial infarction	I21,I22	410
Angina pectoris	I20	411B, 413, 414A
Hypertension	I10-I15	401-405
Tobacco abuse and Chronic Pulmonary Disease	J40-J47,J60-J67,F17, I278,I279,J684,J701,J703	490-496,500-505,416W,416X, 506E,508B,508W,305B

Abbreviations: ICD = International Classification of Diseases.

595
596
597
598

Supplementary Table 2. Cumulative incidence estimates of heart diseases in breast cancer patients and matched controls.

	Cumulative incidence, % (95% CI)					
	6 month	1 year	2 years	5 years	10 years	15 years
Arrhythmia						
Breast cancer	0.86 (0.68-1.08)	1.32 (1.10-1.59)	1.92 (1.65-2.25)	3.60 (3.21-4.04)	7.10 (6.52-7.73)	12.10 (11.12-13.16)
Matched control	0.33 (0.29-0.37)	0.60 (0.55-0.65)	1.15 (1.08-1.23)	2.78 (2.67-2.90)	5.91 (5.75-6.08)	9.60 (9.36-9.86)
Heart failure						
Breast cancer	0.20 (0.13-0.33)	0.45 (0.33-0.62)	0.75 (0.58-0.96)	1.46 (1.21-1.75)	2.93 (2.56-3.35)	5.59 (4.91-6.37)
Matched control	0.08 (0.06-0.10)	0.17 (0.14-0.20)	0.32 (0.29-0.36)	0.86 (0.80-0.93)	2.19 (2.09-2.29)	4.37 (4.19-4.56)
Ischemic heart disease						
Breast cancer	0.46 (0.33-0.63)	0.79 (0.62-1.00)	1.30 (1.08-1.57)	2.57 (2.24-2.95)	4.43 (3.97-4.93)	6.55 (5.85-7.34)
Matched control	0.23 (0.20-0.27)	0.54 (0.49-0.59)	1.07 (1.00-1.14)	2.45 (2.35-2.56)	4.68 (4.54-4.83)	7.01 (6.80-7.22)

599
600
601
602
603

Abbreviations: CI = confidence interval. Cumulative incidence estimates of heart diseases in all breast cancer patients (N = 8338) at different time-points following the index date (= date of diagnosis in breast cancer patients). Cumulative incidence estimates are obtained from Kaplan-Meier survival analyses.

Supplementary Table 3. Hazard ratios for heart diseases by different adjuvant therapies and time since diagnosis

Treatment variables	HR (95% CI) for Arrhythmia		HR (95% CI) for heart failure		HR (95% CI) for ischemic heart disease	
	<10y	>10y	<10y	>10y	<10y	>10y
Radiotherapy						
Right-sided	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)
Left-sided	0.94 (0.76-1.16)	0.83 (0.59-1.16)	1.02 (0.73-1.43)	0.92 (0.57-1.48)	1.10 (0.84-1.44)	1.32 (0.74-2.36)
Missing						
Chemotherapy						
No	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)
Anthracyclines-based	1.02 (0.76-1.36)	1.00 (0.58-1.73)	1.84 (1.19-2.85)	2.31 (1.21-4.43)	1.09 (0.75-1.60)	1.18 (0.48-2.90)
Anthracyclines +Taxanes	0.75 (0.37-1.50)	0.75 (0.10-5.62)	5.08 (2.56-10.06)	0.00 (0.00-.)	1.28 (0.57-2.86)	0.00 (0.00-0.00)
CMF	1.74 (0.93-3.25)	0.72 (0.17-3.00)	1.33 (0.47-3.73)	0.69 (0.09-5.17)	0.67 (0.24-1.85)	0.92 (0.12-7.10)
Type unknown	1.18 (0.86-1.63)	1.09 (0.63-1.89)	1.75 (1.06-2.86)	1.38 (0.66-2.89)	1.47 (0.99-2.19)	1.31 (0.52-3.27)
Missing						
Hormone therapy						
No	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)
Tamoxifen	1.02 (0.77-1.34)	1.10 (0.69-1.77)	0.76 (0.50-1.14)	1.06 (0.58-1.96)	0.82 (0.58-1.16)	1.36 (0.60-3.09)
Aromatase inhibitors	1.09 (0.81-1.48)	1.05 (0.56-1.96)	0.92 (0.60-1.41)	1.62 (0.76-3.46)	1.36 (0.93-1.97)	1.39 (0.48-4.06)
Type unknown	0.76 (0.49-1.20)	1.19 (0.68-2.09)	0.91 (0.49-1.69)	1.08 (0.51-2.29)	1.20 (0.75-1.92)	1.44 (0.54-3.83)
Missing						
Trastuzumab *						
No	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)
Yes	1.48 (0.90-2.43)	0.00 (0.00-0.00)	2.26 (1.20-4.27)	0.00 (0.00-0.00)	1.41 (0.76-2.59)	4.43 (0.39-49.76)
Missing						

Abbreviations: Total No. refers to the total number of patients. N events refers to the number of observed cases. HR = hazard ratio; CI = confidence interval. Hazard ratios are estimated from Cox proportional hazards models with time since diagnosis as underlying time scale. Hazard ratios for model1 are adjusted for age and calendar period. Hazard ratios for model2 are multivariable adjusted including age at diagnosis (years), year of diagnosis (2001/2002, 2003/2004, 2005/2006, 2007/2008), menopausal status (premenopausal, postmenopausal, unknown), Charlson comorbidity index (0, 1, ≥ 2), clinical stage (I, II, III, unknown), type of surgery (no, partial mastectomy, total mastectomy, unknown), history of the specific heart disease, hypertension, chronic pulmonary disease and tobacco abuse, and all treatment variables listed in the table. * Treatment-specific analysis of trastuzumab was restricted to patients diagnosed between 2005 and 2008.

Supplementary Table 4. Hazard ratios for heart diseases by different adjuvant therapies, excluding patients with a history of heart diseases

Treatment variables	Arrhythmia (N = 570)		Heart failure (N =243)		Ischemic heart disease (N =307)	
	N events	HR (95% CI)	N events	HR (95% CI)	N events	HR (95%)
Radiotherapy						
Right-sided	218	REF (1.00)	83	REF (1.00)	99	REF (1.00)
Left-sided	208	0.91 (0.75-1.10)	87	1.01 (0.74-1.36)	118	1.14 (0.87-1.49)
Missing	10		6		5	
Chemotherapy						
No	376	REF (1.00)	133	REF (1.00)	207	REF (1.00)
Anthracyclines-based	83	1.04 (0.79-1.38)	51	1.81 (1.22-2.70)	44	1.15 (0.78-1.68)
Anthracyclines +Taxanes	10	0.92 (0.47-1.79)	13	4.27 (2.18-8.35)	6	1.23 (0.51-2.94)
CMF	6	0.85 (0.37-1.95)	3	0.98 (0.30-3.17)	2	0.51 (0.13-2.11)
Type unknown	87	1.20 (0.89-1.61)	38	1.42 (0.91-2.21)	47	1.41 (0.95-2.10)
Missing	8		5		1	
Hormone therapy						
No	89	REF (1.00)	49	REF (1.00)	43	REF (1.00)
Tamoxifen	298	0.99 (0.76-1.27)	99	0.78 (0.54-1.12)	142	0.98 (0.68-1.42)
Aromatase inhibitors	119	1.06 (0.79-1.42)	61	1.03 (0.68-1.55)	85	1.48 (1.00-2.20)
Type unknown	56	0.91 (0.64-1.30)	29	0.91 (0.55-1.50)	36	1.17 (0.73-1.88)
Missing	8		5		1	
Trastuzumab *						
No	129	REF (1.00)	39	REF (1.00)	60	REF (1.00)
Yes	18	1.21 (0.71-2.04)	13	2.00 (1.02-3.92)	13	1.57 (0.82-2.99)
Missing	93		39		52	

Abbreviations: Total No. refers to the total number of patients. N events refers to the number of observed cases. HR = hazard ratio; CI = confidence interval. Hazard ratios are estimated from Cox proportional hazards models with time since diagnosis as underlying time scale. Hazard ratios are multivariable adjusted including age at diagnosis (years), year of diagnosis (2001/2002, 2003/2004, 2005/2006, 2007/2008), menopausal status (premenopausal, postmenopausal, unknown), Charlson comorbidity index (0, 1, ≥ 2), clinical stage (I, II, III, unknown), type of surgery (no, partial mastectomy, total mastectomy, unknown), and all treatment variables listed in the table. * Treatment-specific analysis of trastuzumab was restricted to patients diagnosed between 2005 and 2008.

Supplementary Figure 1. Flow chart of the data

656 **Supplementary Figure 2.** Cumulative incidence of heart diseases in breast cancer patients and matched reference individuals from the general
657 population.